Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

NCT06414681 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Myelofibrosis，MF

Interventions

DRUG: Tagraxofusp
DRUG: Pacritinib

Sponsor

University of Kansas Medical Center